News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 -
-
-
-
-
-